June 21, 2022
2 min watch
Save
VIDEO: ENZAMET trial offers new directions in metastatic hormone-sensitive prostate cancer
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
In this video, Tanya Dorff, MD, head of the genitourinary cancers program at City of Hope, discusses results from the ENZAMET trial, updated at ASCO Annual Meeting 3 years after it was first presented.
Dorff goes in-depth on the mature data from the trial, which looked into treatment of enzalutamide in metastatic hormone-sensitive prostate cancer, which provided a “consistent benefit” across different subsets.
Dorff also touched on the potential impact this study could have on the way patients with metastatic hormone-sensitive prostate cancer are treated in the future.
Reference:
- Davis I, et al. Updated overall survival outcomes in ENZAMET (ANZUP 1304), an international, cooperative group trial of enzalutamide in metastatic hormone-sensitive prostate cancer (mHSPC). Presented at: ASCO Annual Meeting; June 3-7, 2022; Chicago.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interview
Disclosures:
Dorff reports consulting for Astellas, AstraZeneca, Janssen, Pfizer and Seagen.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.